

## Editor-in-Chief

Dr. Derek J. McPhee  
Amyris Biotechnologies  
E-Mail: mcphee@mdpi.com

## Editorial Board

- Fernanda Borges (Portugal)
- Geoff Brown (UK)
- Ian Churcher (UK)
- Paul Cos (Belgium)
- Paul J. Dyson (Switzerland)
- Thomas Efferth (Germany)
- David R. Gang (USA)
- Arthur Gomtsyan (USA)
- Gilles Gosselin (France)
- Rick Gussio (USA)
- Michael Gütschow (Germany)
- Christian Hartinger (Austria)
- Kenneth A. Jacobson (USA)
- Svend Borup Jensen (Denmark)
- Jos H. M. Lange (The Netherlands)
- Bernard Le Foll (Canada)
- Philip S. Low (USA)
- Giuseppe Mancia (Italy)
- Alberto M. Martelli (Italy)
- Kevin H. Mayo (USA)
- Paolo Montuschi (Italy)
- Mark Murphy (Switzerland)
- Tam Nguyen (USA)
- Mark H. Norman (USA)
- Emmanuel S. Onaivi (USA)
- Ricardo E. Pérez-Tomás (Spain)
- Yvonne Perrie (UK)
- Leonidas A. Phylactou (Cyprus)
- Sally-Ann Poulsen (Australia)
- Thomas Rades (New Zealand)
- Maurizio Recanatini (Italy)
- Hemachandra Reddy (USA)
- Oliver Reiser (Germany)
- Domenico Ribatti (Italy)
- Trudy Rodgers (UK)
- Leandros A. Skaltsounis (Greece)
- Sonia Tucci (UK)
- Jean Jacques Vanden Eynde (Belgium)
- Howard A. Young (USA)
- Liangren Zhang (China)

(Please visit [www.mdpi.com/journal/pharmaceuticals/](http://www.mdpi.com/journal/pharmaceuticals/) editors for an updated list, January 2012)

### Facts about the MDPI Community

70 open access journals  
70 staff at your disposal  
4000 academic editors  
15,000 articles published  
26,000 e-mail alert subscribers  
60,000 unique authors  
150,000 academic peer-reviewers  
600,000 monthly PDF views  
2,400,000 monthly abstract views

MDPI AG  
Postfach  
CH-4005 Basel  
Switzerland

Tel. +41 61 683 7734  
Fax +41 61 302 8918

*Pharmaceuticals* is an independent open access journal published by MDPI

[www.mdpi.com](http://www.mdpi.com)

See [www.mdpi.com/about/contact/](http://www.mdpi.com/about/contact/) for a full list of offices and contact information. MDPI AG is a company registered in Basel, Switzerland, No. CH-270.3.014.334-3, whose registered office is at Kandererstrasse 25, CH-4057 Basel, Switzerland.

# *pharmaceuticals*

## Call for Papers



## Call for Papers

Dear Colleagues,

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Pharmaceuticals* (ISSN 1424-8247). *Pharmaceuticals* is an international, peer-reviewed open access journal on pharmaceutical sciences, including molecular medicine.

Manuscripts prepared in Microsoft Word or LaTeX can be submitted to the Editorial Office online at [www.mdpi.com](http://www.mdpi.com). Detailed Instructions for Authors are also available online:

[www.mdpi.com/journal/pharmaceuticals/instructions/](http://www.mdpi.com/journal/pharmaceuticals/instructions/)

*Pharmaceuticals* is published in open access format—research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public can unlimitedly access the content for free as soon as it is published.

As an open access journal, *Pharmaceuticals* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. More information is available at [www.mdpi.com/about/apc/](http://www.mdpi.com/about/apc/).

We would be pleased to welcome you as one of our authors.

Pharmaceuticals Editorial Office  
E-Mail: [pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)  
Tel. +41 61 683 7734  
[www.mdpi.com/journal/pharmaceuticals/](http://www.mdpi.com/journal/pharmaceuticals/)

## Aims & Scope

*Pharmaceuticals* publishes comprehensive reviews of molecules that are drugs or active pharmaceutical ingredients (API) in one-molecule/class per paper format, and research papers on molecular medicine. Related news and announcements can also be published.

Our aim is to publish as much as possible the theoretical and experimental details. Therefore, there is no restriction on the length of a paper. There are in addition three unique features:

- Manuscripts regarding research proposals and research ideas will be particularly welcomed.
- Electronic files regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, will be deposited as supplementary material.
- Samples of the pharmaceutical products can be deposited into the samples collection of MDPI.

The scope of *Pharmaceuticals* includes:

- Cardiovascular Drugs
- Neuropharmaceuticals
- Gastrointestinal Drugs
- Respiratory Tract
- Antiinfectives
- Endocrine and Metabolic Drugs
- Other Drugs

*Pharmaceuticals* regularly publishes special issues on relevant and timely topics. Be sure to check our website for an updated list of special issues:

[www.mdpi.com/journal/pharmaceuticals/](http://www.mdpi.com/journal/pharmaceuticals/)

## Open Access. What Does It Really Mean?

Open access is mainly a response to what is known as the serials crisis: yearly increasing journal subscription prices, which make subscription-based journals increasingly difficult to afford.

Many university libraries around the world have had to cancel existing subscriptions, or are unable to keep up with subscribing to new journals, because the cost of publication has risen disproportionately to their budgets.

With open access publishing, the cost of peer-review and production of an article is borne by the institute of the author by payment of a one-time flat fee. Conversely, readers and their institutes are no longer charged for accessing the journals they need.

For researchers, open access brings the convenience of immediate access to the literature that they need—no matter for which university or company they work, or whether they just want to read a paper in their spare time at home.

For authors, open access means a much wider circle of readers due to the easy access to their research papers. The interested general public is also able to access research works, giving higher transparency to the outcome of taxpayer money spent on research.